1. A pharmaceutical composition comprising any one or more of the following: i) a soluble glycoprotein CD52, ii) a fusion protein comprising a soluble CD52 glycoprotein as a first protein and a second protein iii) a polynucleotide encoding a peptide portion of the soluble glycoprotein CD52 by rubric i) or a fusion protein of the section and) iv) a vector comprising the polynucleotide of section iii) v) isolated cell comprising the polynucleotide of section iii) or vector of the section iv) vi) an isolated cell CD52, capable of producing a soluble glycoprotein CD52 vii ) Isolated population of cells comprising CD52 plurality of cells capable of producing soluble glycoprotein CD52 viii) a cell culture medium or a fraction containing soluble CD52 glycoprotein, isolated from cell culture comprising a cell according rubric vi) or vii rubric population of cells) iix) an agent capable of increasing the expression level of the soluble glycoprotein CD52 cell and a pharmaceutically acceptable nositel.2. A pharmaceutical composition according to claim 1, wherein the soluble glycoprotein CD52 comprises an amino acid sequence at least 60% identical to the amino acid sequence of any one or more than one of GQNDTSQTSSPS (SEQ ID NO: 3)., SQNATSQSSPS (SEQ ID NO: 4) GQATTAASGTNKNSTSTKKTPLKS (SEQ ID NO: 5), GQNSTAVTTPANKAATTAAATTKAAATTATKTTTAVRKTPGKPPKA (SEQ ID NO: 6) or GNSTTPRMTTKKVKSATPA (SEQ ID NO: 7) and uglevod.3. A pharmaceutical composition according to Claim. 1, wherein the glycoprotein comprises an amino acid sequence that is at least 65%, at least 70%, at least 75%, at least 80%, at least 85% at least 90%, at least 95% identical or 100% identical to any one, and
